BLUE NEVUS MELANOMA FOUNDATION

View Active Grants
GNAQ/GNA11 Oncology

Accelerating targeted therapies for rare melanoma

We fund innovative scientific projects with direct pathways to clinical application, focusing exclusively on tumors driven by GNAQ and GNA11 gene mutations.

Close-up of a high-resolution laboratory environment, a researcher in a white coat operating a precision pipette under cool-toned sterile light, shallow depth of field, 35mm
Close-up of a high-resolution laboratory environment, a researcher in a white coat operating a precision pipette under cool-toned sterile light, shallow depth of field, 35mm
Translational Science

The UCSF research partnership

In collaboration with leading oncologists at the University of California, San Francisco, we translate laboratory discoveries directly into human clinical trials. This alliance bridges the gap between basic molecular biology and active patient care.

By focusing on drug repurposing and novel drug discovery, we bypass traditional multi-decade development timelines to bring viable options to patients with urgent clinical needs.

Active Grants

Funding GNAQ/GNA11 research

Our current portfolio targets the specific genetic drivers of blue nevus melanoma, prioritizing projects with immediate clinical trial potential.

Drug Repurposing

Personalized Vaccines

Novel Drug Discovery

Screening existing oncology libraries to identify approved compounds that effectively inhibit GNAQ/GNA11 mutant pathways.

Funding patient-specific cancer vaccine development designed to train the immune system against unique tumor neoantigens.

Supporting high-throughput screening of novel small molecules designed to selectively block oncogenic signaling cascade.

Join the Registry

Uniting science and patient data

Every patient registry entry provides critical molecular data that attracts pharmaceutical investment and accelerates clinical trials. Join our mission to fund the cure.